HOME Top Market Reports Drug - Device Combination (2009 - 2014)

Drug - Device Combination (2009 - 2014)

By: marketsandmarkets.com
Publishing Date: November 2009
Report Code: MD 1009

Discount on Reports  

  Speak to Analyst Enquiry Before Buying  
purchase report
download pdf  request for customisation

Report Description

Drugs and devices have emerged as a combination product in the 21st century. Today, the medical industry has completely adopted the drug-device combination; and the U.S. Food and Drug Administration (USFDA) and other similar governing bodies across the globe have given their approval for the marketing of these products.

The market for drug-device combination was over $9 billion in 2008 and is expected to grow at a double digit CAGR in the next few years. Therefore, a detailed analysis of this market will benefit stakeholders not only through comprehensive market statistics, but also through the strategic recommendations this report makes, based on a detailed market study and exchange of market knowledge with industry experts. Our analysis would help companies and commercial pharma research labs get in-depth information about the recent developments and upcoming trends, as well as the opportunities, drivers, and restraints in each segment of the global drug-device combination market.

The existing studies and third-party market reports do not provide a comprehensive understanding and classification of the drug-device combination market, such as hernia repair and artificial pancreas. This report divides the market into smaller product segments which none of the other third party reports have done so far.

Scope of the report

This report categorizes the drug-device combination market by products, applications, and technology, each of which is further categorized into its individual submarket. The drug-device products segment, for instance, covers the submarkets for antimicrobial catheters, advanced wound care products, bone graft substitutes, antibiotic bone cement, drug eluting stents, photodynamic therapy, closed loop glucose monitor and insulin pump, steroid eluting electrodes and others.

The report offers more than 100 market tables and sizes all the submarkets for the four major markets of the U.S., Europe, Asia, and Rest of the World. The report highlights key opportunity areas for the relevant stakeholders; and also identifies the market trends, drivers, and inhibitors for each segment. The report charts the major competitive developments in the drug-device combination market, and provides more than 50 company profiles for a deeper insight into the market’s competitive landscape.

What makes our reports unique?

  1. We provide the longest market segmentation chain in the industry with our three-level market breakdown and our analysis of minimum 40 collectively exhaustive and mutually exclusive micro markets.
  2. We provide 10% customization to ensure that our clients find the specific market intelligence they need.
  3. Each report is about 150 pages, featuring 30+ market data tables, 30+ company profiles, and an analysis of 200 patents.
  4. No single report by any other publisher provides market data for all market segments (i.e. products, services, applications, ingredients, and technology) covering the four geographies of North America, Europe, Asia Pacific, and ROW.
  5. 15 pages of high level analysis identifying opportunities, best practices, entry strategies, benchmarking strategies, market positioning, product positioning, and competitive positioning.

Key questions answered

  1. Which are the high-growth segments and how is the market segmented in terms of applications, products, services, ingredients, technologies, stakeholders?
  2. What are market estimates and forecasts; which markets are doing well and which are not?
  3. Where are the gaps and opportunities; what factors are driving market growth?
  4. Which are the key playing fields and winning-edge imperatives?
  5. What is the competitive landscape; who are the main players in each segment; what are their strategic directives, operational strengths, key selling products, and product pipelines? Who is doing what?

Powerful Research and analysis

The analysts working with MarketsandMarkets come from renowned publishers and market research firms globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies.

Table Of Contents

  1.1 Key take-aways 
  1.2 Report description
  1.3 Markets Covered
  1.4 Stakeholders


  3.1 Evolution of drug-device combination 
  3.2 Driving factors analysis for drug-device combination market
  3.3 Drivers
      3.3.1 Increased efficiency 
      3.3.2 Exploiting existing technologies 
      3.3.3 Accelerated approval process 
      3.3.4 Medical insurance coverage 
      3.3.5 Rising awareness 
  3.4 Restraints
      3.4.1 Issues involved in cross industry partnerships 
      3.4.2 Drug-device combination products are expensive 
      3.4.3 Jurisdiction issues 
      3.4.4 Fear of possible side-effects
  3.5 Opportunities
      3.5.1 Reduction in investment costs 
      3.5.2 Streamlining issues in partnerships 
      3.5.3 Reduction in the overall cost of treatment 
      3.5.4 Market participation by smaller companies

  4.1 Antimicrobial catheter
      4.1.1 Drivers 
   Reduced incidences of infection in intensive care 0units
   Over all cost reduction 
   Certain catheters are prone to infections 
   Reimbursement issues 
   Presence of big players in the antimicrobial catheters market 
   Awareness of antimicrobial agents used for coating on the catheters 
   Demand unaffected by the economic downturn
      4.1.2 Restraints
   Price constraints 
   Lack of awareness in developing countries implementation of standard solutions
      4.1.3 Key players & their recent developments 
      4.1.4 Urological catheters
           Prevention of several nosocomial infections 
           Beneficial for women and baby boomers 
           Reduced health care costs 
           Increased applications 
           Alternatives to prolonged catherization 
           Reimbursement issues 
           Key players and their recent developments
   Dialysis catheter
           Key players and their recent developments
           Hemodialysis catheters 
           Peritoneal catheters
   Urinary catheters
           Key players and their recent developments 
           Indwelling cathetersExternal catheter
                  Drivers & restraints
                     Key players & their recent developments
           External catheter
      4.1.5 Cardiovascular catheters
           Indispensability associated with these catheters 
           Suitable in emergency operations 
           Rising number of obesity aiding the growth of the procedures that use these products 
           Interventional procedures have better success ratio
           Usage avoided due to high cost and subsequent reimbursement issue 
           Incidence of infections due to the use of non-antimicrobial coated catheter not known
           Competition from new technologies & devices
           Awareness of surgeons 
           Resolving reimbursement structure 
           Decreasing prices 
      4.1.6 Oximetry catheters
           Reduction in catheter related blood stream infections
           Prolonged fight against micro organisms 
           Overall cost of hospitalization will go down
           Popularity of uncoated variant 
           Key players and their recent developments
      4.1.7 Thermodilution catheters
           Fatal infections are avoided 
           Increased usage likely in near future 
           Increasing complications of the heart
           Uncoated thermodilution catheters are cheaper
           Fear of resistance from microorganism strains
           Innovations in pharmaceutical therapies
     4.1.8 Wound drainage catheters
          Useful in several surgeries 
          Protection from wide variety of micro organisms 
          Elimination of the risk of nosocomial infections on the wound sites
          Proper handling required
 4.2 Advanced Wound Care Products
     4.2.1 Drivers 
  Multiple advantages over conventional wound care products 
  Supports healing process of the skin 
  Advanced gel based products accelerate healing process 
  Prevention of bacterial colonization on sutures 
  Reduction in the cost of hospitalization 
  Less frequent change of dressings required 
     4.2.2 Restraints 
  Lack of product differentiation leading to price wars 
  Minimally invasive surgeries are stunting the demand of wound-care products
     4.2.3 Opportunities
  Focus on research 
  Raise awareness of the care providers 
  Specially developed wound dressing products
     4.2.4 Key players and their recent developments
     4.2.5 Antibiotic wound care
          Treatment is conducive for wide range of patients
          Low risk of infections as silver is an ingredient in the product 
          Nanotechnology paves the way for improved formulations 
          Cost constraint 
          Reimbursement issues 
          Rising awareness about the risk of infections
          Edification of medical practitioners 
          Ageing baby boomers 
  Key players and their recent developments
 4.3 Bone Graft Substitutes
     4.3.1 Drivers 
  Shortage of donors 
  Substitutes satisfying ideal properties of bone 
  Virtual elimination of the risk of infection 
  Improved life expectancy 
  Increasing need for orthopedic procedures
     4.3.2 Restraints 
  ‘One size fits all’ approach not possible 
  Procedure not affordable for all
     4.3.3 Key players and their recent developments 
     4.3.4 Ceramic based bone graft substitute
          Most popular bone graft substitutes 
          Compatibility with new technology 
          Risk of transference of fatal diseases eliminated
          Availability in various forms gives wider choice for applications 
          Close proximity of composition to natural bone 
          Stand alone ceramic products are brittle 
          Application limited to non load bearing sites
          Newer technology stunting the stand alone ceramics market
  Ceramic based bone graft substitutes mixed with calcium phosphate
          Key players and their recent developments 
  Allograft based bone graft substitutes
                    Totally natural enables faster healing 
                    Wide array of choice for various applications
                    Extraction of DBM helps in spine fusion 
                    Localized application of DBM enables faster healing 
                    Risk of disease diffusion not entirely eliminated
                    Success depends on the site of application 
                    Wider adoption of new technology
          Key players and their recent developments
  Factor based bone graft substitute
                    Cellular activity made possible in the bone
                    Removal of risks of toxicity 
                    Availability of supporting technology 
                    Several products yet to receive marketing approval
                    No guaranteed results 
                    Production process incurs high cost 
                    Effectiveness in treating spinal fusion 
                    More ‘factors’ to boost the market
          Key players and their recent developments
  Cell based bone graft substitutes
                    Most adaptive to human body among all bone graft substitute variants 
                    Faster healing 
                    Simple process of extraction 
                    Limited results in practice 
                    Supporting technologies not available 
                    Several regulatory issues yet to be resolved 
                    Successful results 
                    Advancement in supporting technologies
          Key players and their recent developments
 4.4 Antibiotic Bone Cements
     4.4.1 Drivers 
  Faster healing because of localized treatment 
  Prevention of infections 
     4.4.2 Restraints  
  Low bacterial resistance 
  Prone to allergic reactions 
     4.4.3 Key players and their recent developments 
 4.5 Drug Eluting Stents
     4.5.1 Drivers 
  Increased life expectancy 
  Interventional procedures have higher effectiveness
  Global acceptance of drug eluting stent technologies
  Reduces the need for repeat procedures 
     4.5.2 Restraints  
  Risk of clots for some patients 
  Adoption of better cholesterol fighting drugs 
  Bare metal stents cheaper than drug eluting  stents 
     4.5.3 Opportunities
  FDA’s support for drug eluting stents 
  New generation drug eluting stent
     4.5.4 Key players and their recent developments 
     4.5.5 Coronary stents  
          Growing popularity of minimally invasive surgery
          Prevention of reblockage 
          Reduced instances of deathsby heart attacks
          Diminished need for repeated procedures 
          Obesity and other factors driving cardiac related issues
                  Limited applications 
                  ‘Off-label’ applications 
                  Increased restrictions following controversy 
                  Possibility of side effects due to drug therapy following surgery 
          Possibility of increased applications 
          Supporting technology reduces the risk of in-stent late thrombosis
  Key players and their recent developments
     4.5.6 Peripheral vascular stent
          Alleviation of pain in the aged population 
          Severe results are eliminated 
          Prevalence of cigarette smoking acts as a driver 
          Limited data available due to ignorance of the disease 
          Lack of awareness of physicians 
  Key players and their recent developments
 4.6 Photodynamic Therapy
     4.6.1 Drivers 
  Localized treatment increases the effect of the therapy
  Less time gap between consumption of drug and light treatment
  Advantages over antibiotics 
  Treatment is inexpensive 
     4.6.2 Restraints 
  Competition from traditional treatments 
  Side effects 
     4.6.3 Opportunities
  Advanced research will help to treat larger solid tumors
  Promising field of non invasive anti tumor therapy
     4.6.4 Key players and their recent developments 
     4.6.5 Aminolevulinic acid
          Accuracy in treatment 
          Increase in potential size 
          Increased potential in selected markets
          Minimally invasive nature is attractive 
          New avenues of treatment 
          Cheaper than other alternatives
          Application limited to selected areas of the body 
          Prone to photosensitivity 
          Other more efficient treatments are available
          Application limited to certain geographical areas
          Innovation will lead to better results 
     4.6.6 Porfimer sodium
          A popular form of treatment
          No long term side effects
          Number of applications 
          Treatment suitable for patients who do not qualify for other treatments 
          Treatment is not independent 
          Success depends upon the stage of the disease
          Treatment eliminates extensive forms of cancer
          Presence of side effects 
  Key players and their recent developments
     4.6.7 Verteporfin
          Treats macular degeneration of the wet type 
          Targeted treatment is effective on diseased area
          Repeated procedures required 
          New inventions in drug therapy 
          Possible risk 
          Side effects associated with drug therapy 
          New developments eliminate the need for repeat procedures
  4.7 Steroid Eluting Electrodes
      4.7.1 Drivers 
   Increasing demand for pacemakers and ICDs
   Continuously monitors the heart 
   Increased longevity 
      4.7.2 Restraints  
   Advantages of non steroid eluting electrodes 
   Monopoly by a few companies 
      4.7.3 Key players and their recent developments 
      4.7.4 Implantable cardioverter defibrillator
           Prevention of inflammation 
           Improved diagnosis of cardiac problem
           Limited choice in product variety 
           Restrained promotion about their effectiveness
      4.7.5 Deep brain stimulator
           Treatment provides therapeutic benefits 
           Varied applications
           Fear of side effects
 4.8 Closed Loop Glucose Monitor and Insulin Pump
     4.8.1 Drivers 
  Minimal invasiveness leads to convenience 
  Hassle free diabetes management 
  Treatment made reliable 
  A killer disease 
  Monitoring of diabetes combating therapies 
  Monitoring of extreme levels of glucose 
  Insurance coverage 
     4.8.2 Restraints  
  Human intervention necessary 
  The combination product expensive 
  New technology 
     4.8.3 Opportunities
  Under penetration of the product in the U.S. 
  Further development of technology
     4.8.3 Key players and their recent developments 
  5.1 Cardiovascular Treatment
      5.1.1 Drivers 
   Provide better treatment 
   Increasing number of cardiovascular treatments
   Increased comfort to the elderly 
   Diabetes patients with cardiovascular problems
      5.1.2 Restraints
   Restriction enforced by FDA 
   Post surgery medication adds up to the cost 
   Prevention of cardiovascular diseases
      5.1.3 Coronary angioplasty
           Reduced risk of sudden heart attacks 
           Treatment independent of economic situation
           Not recommended for angina 
           Expensive nature of treatment
      5.1.4 Tachycardia management
           Reduced chances of heart failure 
           Diagnosis has opened up new avenues
           Unknown potential market size 
           Lack of awareness
      5.1.5 Pediatric bradycardia
 5.2 Non-Cardiovascular Treatments
     5.2.1 Drivers 
  Several new treatments for non-cardiovascular diseases
  Issue of reimbursement 
  Untapped markets 
  Reap full potential of present technologies
     5.2.2 Restraints 
  Partnership issues 
  Rising popularity of alternative therapies 
  Underlying cause of disease not known
     5.2.3 Peripheral arterial disease (PAD)
  Symptoms of the disease are often confused with general problems of old age
     5.2.4 Intravascular access
          Indispensable in modern day medical imstitutions
          Prevents infection along with serving other purposes
          Agents used to coat the catheters have already been tested 
          New developments give increased mobility
          Following guidelines for use of uncoated catheters eliminates need for coated ones 
          Increasing minimally invasive surgeries
     5.2.5 Intravascular access
          New opportunities 
          Large segment of population afflicted with the disease
 5.3 Urological Treatments
     5.3.1 Drivers 
  Wide array of applications 
  Various factors boost the market 
  Improved efficiency of new treatments
     5.3.2 Restraints 
  Urological diseases overshadowed by cardiovascular diseases
     5.3.3 Dialysis
          High per capita revenue 
          Reimbursement plans activated 
          Convenience associated with home dialysis
     5.3.4 Urinary tract infections
          Women prone to such infections 
          Prevention better than cure
          Diagnosing urinary tract infections is still an issue
 5.4 Bone Treatment
     5.4.1 Drivers 
  High success ratio to drive the market
  Degenerative diseases to push the market forward 
  Several factors are promoting their usage 
  Transmission of fatal diseases can be avoided
     5.4.2 Restraints
  Therapies are not of the same standard as allograft and autografts
     5.4.3 Joint arthroplasty
          Deep prosthetics infections reduced to 1.6% from 6%
          Obesity increasing the demand for joint arthroplasty
          Improved accuracy gives confidence to its application
          Rising necessity of revision surgeries
     5.1.4 Spine fusion
 5.5 Antimicrobial Applications
     5.5.1 Drivers 
  Application is increasing over time 
  Rising number of diabetic patients 
  Infection prevention leads to faster recovery 
  Reduced expenditure incurred by hospitals
     5.5.2 Restraints 
  Lack of resources in urban safety-net hospitals 
  Developing countries have not adopted these treatments
     5.5.3 Wound care
          Several factors giving boost to the market 
          Slowing down in demand is not possible
     5.5.4 Skin substitutes
          Infection risk is eliminated 
          Faster healing reduces period of convalescence
          Reimbursement issue is a restraining factor
 5.6 Cancer Treatment
     5.6.1 Drivers 
  Increase in the number of cancer patients 
  Treatment using PDT is non invasive and patient friendly 
  Risks associated with the treatment is minimal 
  Treatment without risk of side effects
     5.6.2 Restraints 
  Limited applications 
  Possibility of inadequate number of health care professionals 
  New pharmaceutical inventions
     5.6.3 Barrett’s esophagus
          Increasing prevalence of the disease 
          Several advantages of the treatment 
          Improved efficiency of the treatment
     5.6.4 Skin cancer
          Increased diagnosis of skin cancer cases will give a boost to the market 
          Broadening variety of cancer patients 
          Prevalence of such cancer in developed countries 
          Application not limited to one disease 
          Limited market potential 
     5.6.5 Head and neck cancer
          Preferred treatment in certain cases 
          Less risk of long term infections
          Patients revert to conventional treatments if cancer relapses 
          Low success rate due to co morbidity
 5.7 Skin Care/Treatment
     5.7.1 Drivers 
  Increasing demand for skin care therapy
  Treatment is done at the inner dermis layer
     5.7.2 Restraints 
  Loyal customers of cosmetic companies 
  Limited marketing activities for PDT
     5.7.3 Opportunities
  Improved marketing activities
  Untapped potential in developing countries
     5.7.4 Actinic keratoses
          High demand in the U.S. and Australia
          Enhanced treatment
          Elimination of risk of skin cancer
          Added advantage of cosmetic enhancement
          Demand is not global
          Repeated procedures make the patients photosensitive
     5.7.5 Photorejuvenation
 5.8 Ophthalmic Treatment
     5.8.1 Drivers 
  Increased demand from the ageing population
  Offers physical and economical advantages
     5.8.2 Restraints 
  Repeated treatments required
     5.8.3 Pathologic myopia
          One of the leading causes of blindness in people of certain races
          Photodynamic therapy is an alternative option
          Increased preference by sportspersons
          Repetetion of procedures will add to the cost
          Preference of contact lenses over PDT
     5.8.4 Age related macular degeneration
          Age related macular degeneration has the potential of becoming a national health issue
          Non invasive nature leads to no pain and inconvenience
          No damage to the retina
          Success restricted by certain factors
          Non recovery of normal 6/6 vision 
     5.8.5 Presumed ocular histoplasmosis
 5.9 Diabetes Treatment
     5.9.1 Drivers 
  Increasing number of diabetes patients
  Potential in middle income countries
  New generation treatments effective in diabetic patients
     5.9.2 Restraints 
  Possible restraining factors in future
  Limited opportunity in Africa
     5.9.3 Opportunities
  Obesity and increasing age of people
  Development in technologies will reduce the cost
  6.1. Synthetic Bone Graft Substitutes
       6.1.1. Drivers 
     Availability of several types enables customized usage 
     Surgeons have several options
     Applicable in load bearing body parts 
     Foreign substance eliminated from the body
     Increased applications
       6.1.2. Restraints  
     Do not possess ideal properties
     Possible stunted growth in future
  6.2. Synthetic Bone Graft Substitutes
       6.1.1. Drivers 
     Easy to understand technology
     Applicable for different types of bone defects
     Growing number of aged people
       6.2.2. Restraints
     Lack of osteoinductive properties
     Competition from other procedures
  6.3. Bone Morphogenic Proteins 

  7.1. The U.S. Drug-device Combination Market  
  7.2. The European Drug-device Combination Market 
  7.3. The Asian Drug Device Combination Market

  8.1 3M
  8.15 C.R. BARD, INC.
  8.20 CORIN
  8.21 COVALON
  8.23 DAVOL INC.
  8.27 ETEX
  8.28 ETHICON, INC.
  8.39 QLT INC.
  8.45 SYNTHES, INC.
  8.47 VYGON S.A
  8.50 XTENT

  9.1. U.S. Patents
  9.2. E.U. Patents
  9.3. ASIA Patents


1 Parental structure of drug-combination market
2 Evolution of drug-device combination
3 Factors affecting the drug-device combination market
4 Current favorability for drug-device combination market
5 Market potential for drug-device combination market
6 Trends in r&d for drug-device combination market
7 Global market share of key players
8 Global segmentation of drug-device combination patents

1 Global antimicrobial catheter market, by products 2007 – 2014 ($Millions)
  1a Global antimicrobial catheter market, by thousands of units 2007 – 2014
2 Global antimicrobial catheter market, by geography 2007 – 2014 ($Millions)
3 Major players and product developments
4 Global urological catheter market, by products 2007 – 2014 ($Millions) 
  4a Global urological catheter market, by product by thousands of units 2007-2014
  4b Global urological catheter market, by polymers 2007 – 2014 ($Millions)
5 Global urological catheter market, by geography 2007 – 2014 ($Millions)
6 Major players and product developments
7 Global dialysis catheter market, by products 2007 – 2014 ($Millions)
  7a Global dialysis catheter market, by product by thousands of units 2007-2014
  7b Global dialysis catheter market, by polymers 2007 – 2014 ($Millions)
8 Global dialysis catheter market, by geography 2007 – 2014 ($Millions)
9 Major players and product developments
10 Global hemodialysis catheter market, by geography 2007 – 2014 ($Millions)
11 Global peritoneal catheter market, by geography, 2007 – 2014 ($Millions)
12 Global urinary catheter market, by products 2007 – 2014 ($Millions)
   12a Global urinary catheter market, by products, by thousands of units 2007-2014
   12b Global urinary catheter market, by polymers 2007 – 2014 ($Millions)
13 Global urinary catheter market, by geography 2007 – 2014 ($Millions)
14 Major players and product developments
15 Global indwelling catheter market, by geogrphy 2007 – 2014 ($Millions)
16 Major players and product developments
17 Global external catheter market, by geography 2007 – 2014 ($Millions)
18 Global oximetry catheter market, by products 2007 – 2014 ($Millions)
19 Global thermodilution catheter market by geography 2007 – 2014 ($Millions)
20 Major players and product developments
21 Global advanced wound care products market, by products 2007 – 2014 ($Millions)
   21a Global advanced wound care market, by product, by thousands of units 2007-2014
   21b Global advanced wound care market, by materials 0f construction 2007 – 2014 ($Millions)
22 Global advanced wound care products market, by geography 2007 – 2014 ($Millions)
23 Major players and product developments
24 Global antibiotic wound care market, by geography 2007 – 2014 ($Millions)
25 Major players and product developments
26 Global bone graft substitues market, by products 2007 – 2014 ($Millions)
27 Global bone graft substitues market, by geography 2007 – 2014 ($Millions)
28 Major players and product developments
29 Global ceramic based bone graft substitutes market, by products 2007 – 2014 ($Millions)
30 Global ceramic based bone graft substitutes market, by geography 2007 – 2014 ($Millions)
31 Global ceramic based bone graft substitutes mixed with calcium phosphate market, by geography 2007 – 2014 ($Millions)
32 Major players and product developments
33 Global allograft based bone graft substitutes market, by geography 2007 – 2014 ($Millions)
34 Major players and product developments
35 Global factors based bone graft substitutes, by geography 2007 – 2014 ($Millions)
36 Major players and product developments
37 Global cell based bone graft substitutes market by geography 2007 – 2014 ($Millions)
38 Major players and product developments
39 Global antibiotic bone cements market, by geography 2007 – 2014 ($Millions)
40 Major players and product developments
41 Global drug eluting stents market, by products 2007 – 2014 ($Millions)
   41a Global drug eluting stents market, by product by thousands of units 2007 – 2014
42 Global drug eluting stents market, by geography 2007 – 2014 ($ Millions)
43 Global coronary stents market, by geography 2007 – 2014 ($Millions)
44 Major players and product developments
45 Global peripheral vascular stent market by geography 2007 – 2014 ($Millions)
46 Global photodynamic therapy market, by products 2007 – 2014 ($Millions)
47 Global photodynamic therapy market, by geography 2007 – 2014 ($Millions)
48 Major players and product developments
49 Global aminolevulinic acid market, by geography 2007 – 2014 ($Millions)
50 Global porfimer sodium market, by geography 2007 – 2014 ($Millions)
51 Major players and product developments
52 Global verteporfin market, by geography 2007 – 2014 ($Millions)
53 Global steroid eluting electrodes market by products 2007 – 2014 ($Millions)
   53a Global steroid eluting electrodes market, by products by thousands of units 2007 – 2014
54 Global steroid eluting electrodes market by geography 2007 – 2014 ($Millions)
55 Major players and product developments
56 Global implancardioverter market, by geography 2007 – 2014 ($Millions)
57 Global deep brain stimulator market, by geography 2007 – 2014 ($Millions)
58 Global closed loop glucose monitor and insulin pump market, by geography 2007 – 2014 ($Millions)
59 Major players and product developments
60 Global cardiovasular treatment market, by applications 2007 – 2014 ($Millions)
61 Global non cardiovascular treatment market, by applications 2007 – 2014 ($Millions)
62 Global urologicaltreatment market, by applications 2007 – 2014 ($Millions)
63 Global bone treatment market, by applications 2007 – 2014 ($Millions)
64 Global antimicrobial applications market 2007 – 2014 ($ Millions)
65 Global cancer treatment market, by applications 2007 – 2014 ($Millions)
66 Global skin care/treatment market, by applications 2007 – 2014 ($Millions)
67 Global ophthalmic tretment market, by applications 2007 – 2014 ($ Millions)
68 Global bone graft substitutes market, by technology 2007 – 2014 ($Millions)
69 Global drug-device combination market 2007 – 2014 ($Millions)
70 U.S. drug-device combination market, by products 2007 – 2014 ($Millions)
   70a U.S. drug-device combination market, by product by thousands of units 2007 – 2014
71 European drug-device combination market, by products 2007 – 2014 ($Millions)
   71a European drug-device combination market, by product by thousands of units 2007 – 2014
72 Asian drug-device combination market, by products 2007 – 2014 ($Millions)
   72a Asian drug-device combination market, by product, by thousands of units 2007-2014
73 3M’s product portfolio
74 3M strategies
75 Abbott laboratories’ product portfolio
76 Abbott laboratories strategies
77 Acrymed’s product portfolio
78 Agion technologies product portfolio
79 Agion technologies, inc. strategies
80 Allosource’s product portfolio
81 Allosource strategies
82 Angiotech pharmaceuticals’ product portfolio
83 Angiotech pharmaceuticals strategies
84 Apatech’s product portfolio
85 Arrow international’s product portfolio
86 Atrium medical’s product portfolio
87 Atrium medical strategies
88 Biomet orthopedics’ product portfolio
89 Biometrix’s product portfolio
90 Biosensors’ product portfolio
91 Biosensors strategies
92 Biotronik’s product portfolio
93 Biotronik strategies
94 Boston scientific’s product portfolio
95 Boston scientific strategies
96 C.R. bard’s product portfolio
97 Biotronik strategies
98 Collagen’s matrix product portfolio
99 Cook critical care’s product portfolio
100 Cook medical’s product portfolio
101 Cook medical strategies
102 Cordis corporation’s product portfolio
103 Corin product portfolio
104 Corin strategies
105 Covalon’s product portfolio
106 Covalon strategies
107 Covidien’s product portfolio
108 Covidien strategies
109 Davol’s product portfolio
110 Depuy orthopaedics’ product portfolio
111 Dusa pharmaceuticals’ product portfolio
112 Dusa pharmaceuticals strategies
113 Edwards lifesciences product portfolio
114 Etex’s product portfolio
115 Etex strategies
116 Ethicon’s product portfolio
117 Exactech’s product portfolio
118 Integra lifesciences product portfolio
119 Integra lifesciences strategies
120 Kiadis pharma’s product portfolio
121 Lifecell corp.’s product portfolio
122 Medtronic’s product portfolio
123 Medtronic strategies
124 Nucryst pharmaceuticals product portfolio
125 Orbusneich co., ltd. product portfolio
126 Organogenesis, inc’s product portfolio
127 Osteotech, inc.’s product portfolio
128 QLT’s product portfolio
129 Smith & nephew’s product portfolio
130 Smith & nephew strategies
131 Spire biomedical’s product portfolio
132 St. jude’s product portfolio
133 St. jude strategies
134 Stryker’s product portfolio
135 Sungwon’s medical product portfolio
136 Synthes product portfolio
137 Tei biosciences product portfolio
138 Vygon’s product portfolio
139 W.L. gore & associates product portfolio
140 W.L. gore & associates strategies
141 Wright medical’s product portfolio
142 Xtent’s product portfolio
143 Zimmer’s product portfolio
144 Zimmer strategies

Drug Device Combination – a High Growth Market

Drug-device combination is defined as the combination of drugs and medical devices that can be chemically or physically united or co-packaged as separate, cross labeled products. The commercialization cycle from R&D to product shows the immense potential of the bundled offering. Currently, the market has a potential of US$10.6 billion and has been experiencing a growth of 15% CAGR for the past two years. In the next five years, the market is expected to grow at a CAGR of 11.8%. A future view of the drug-device combination is that these products will make single component medical devices obsolete.

The drug-eluting stents (DES) market is the largest segment in the drug-device combination market. This is supported by the fact that cardiovascular applications constitute about 64% of the entire drug-device combination applications market. However, it is the relatively smaller market of antimicrobial catheter that offers the highest growth potential over the next five years in the overall market.


Source: MarketsandMarkets

The DES market is further segmented into stent grafts, coronary stents and peripheral vascular stents. Though coronary stents has the highest market share, peripheral vascular stents is expected to have the highest growth rate till 2014. The fastest growing macro-market of antimicrobial catheter is segmented into micro-markets such as urological catheter, cardiovascular catheter, peripherally inserted central catheter, oximetry catheter, thermodilution catheter and wound drainage catheter. Closed loop glucose monitor and insulin pump is also expected to record a high growth rate for the period 2009 to 2014. The two major segments: steroid eluting electrodes and photodynamic therapy are estimated to see the slowest growth rate due to a slow development of new products in these markets.

The challenges crippling the growth of the market in the future are expected to be the issues involved in cross industry partnerships, jurisdiction issues, patient safety and interoperability issues.

The drug-device combination market is not fragmented and the key players in this market are Medtronic, Boston Scientific Corp., Edwards Life sciences Corp., Stryker Corp., QLT Inc. etc. The maximum number of new product developments is expected to take place in the bone graft substitutes, advanced wound care products and antimicrobial catheter markets. Our patent analysis indicates that E.U. has filed for the maximum number of patents followed by the U.S.

There is an immense scope of collaboration between the drugs and medical devices companies in the areas of closed loop glucose monitor and insulin pump, bone graft substitutes and advanced wound care products market. However, the antibiotic bone cements and advanced wound care market is expected to face stiff competition in the next five years to come.

The incremental benefits of these combination products over the regular medical devices are increased efficiency, reduction in overall cost of treatment along with the rising awareness. The market holds significant opportunity for the early movers albeit with extensive research to develop new and improved products at competitive prices. Successful strategic alliances between companies from the drugs and medical devices areas assist them in taking advantage of the existing technologies by avoiding capital expenditure in R&D and take the drug-device combination market to new heights.

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support

US : 1-888-600-6441
UK : 44-800-368-9399

Search reports